We are live on ! Find out more
IDNA icon

iShares Genomics Immunology and Healthcare ETF

47 hedge funds and large institutions have $44.1M invested in iShares Genomics Immunology and Healthcare ETF in 2025 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 17 increasing their positions, 11 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

55% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 11

0.87% more ownership

Funds ownership: 40.86%41.73% (+0.87%)

0% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 7

1% less capital invested

Capital invested by funds: $44.4M → $44.1M (-$290K)

2% less funds holding

Funds holding: 4847 (-1)

Holders
47
Holders Change
-1
Holders Change %
-2.08%
% of All Funds
0.62%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
7
Increased
17
Reduced
11
Closed
7
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
UBS Group
1
UBS Group
Switzerland
$11.3M +$970K +48,180 +10%
WBG
2
Wharton Business Group
Pennsylvania
$5.96M +$106K +5,255 +2%
Bank of America
3
Bank of America
North Carolina
$5.54M -$98.1K -4,870 -2%
Raymond James Financial
4
Raymond James Financial
Florida
$2.78M +$208K +10,314 +8%
Morgan Stanley
5
Morgan Stanley
New York
$2.7M -$4.12M -204,614 -61%
PGA
6
Portland Global Advisors
Maine
$2.1M +$2.06M +102,323 New
Royal Bank of Canada
7
Royal Bank of Canada
Ontario, Canada
$1.52M +$12.6K +627 +0.9%
CCA
8
Clearwater Capital Advisors
Illinois
$1.38M -$373K -18,525 -22%
Ameriprise
9
Ameriprise
Minnesota
$1.35M -$15K -745 -1%
LPL Financial
10
LPL Financial
California
$954K +$95.5K +4,741 +11%
FTUS
11
Flow Traders U.S.
New York
$931K +$914K +45,404 New
Jane Street
12
Jane Street
New York
$904K +$888K +44,071 New
Susquehanna International Group
13
Susquehanna International Group
Pennsylvania
$851K +$36.3K +1,804 +5%
CCA
14
Cora Capital Advisors
New Jersey
$799K -$88.5K -4,396 -10%
Lido Advisors
15
Lido Advisors
California
$698K -$319K -15,823 -32%
Commonwealth Equity Services
16
Commonwealth Equity Services
Massachusetts
$640K +$9.87K +490 +2%
USCWA
17
U.S. Capital Wealth Advisors
Texas
$609K +$91.7K +4,552 +18%
AWM
18
Avior Wealth Management
Nebraska
$574K +$4.67K +232 +0.8%
Cambridge Investment Research Advisors
19
Cambridge Investment Research Advisors
Iowa
$472K +$65.1K +3,233 +16%
PCA
20
Prosperity Capital Advisors
Ohio
$457K +$96.6K +4,798 +27%
Wells Fargo
21
Wells Fargo
California
$306K +$18.1K +899 +6%
OWM
22
Opes Wealth Management
California
$296K
Cetera Investment Advisers
23
Cetera Investment Advisers
Illinois
$234K +$11.2K +554 +5%
M
24
MATAURO
New York
$204K +$1.47K +73 +0.7%
Jones Financial Companies
25
Jones Financial Companies
Missouri
$179K +$16.1K +797 +10%

IDNA Hedge Fund Activity: Q2 2025 in Review

47 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in iShares Genomics Immunology and Healthcare ETF (IDNA) for Q2 2025, worth a combined $44.1M — down 0.65% from $44.4M a quarter earlier.

Fund positioning in IDNA was balanced in Q2 2025: 7 funds opened new positions, 7 closed out, 17 added to existing stakes and 11 trimmed.

The largest buyer was Portland Global Advisors, opening a new position worth an estimated $2.06M. The largest seller was Morgan Stanley, cutting an estimated $4.12M.

  • 47 institutional investors held iShares Genomics Immunology and Healthcare ETF (IDNA) as of Q2 2025, down from 48 in Q1 2025.
  • Funds reported $44.1M of iShares Genomics Immunology and Healthcare ETF stock for Q2 2025, down 0.65% quarter-over-quarter.
  • 7 funds opened new iShares Genomics Immunology and Healthcare ETF positions in Q2 2025 and 7 closed out, a net change of 0 holders.
  • The largest iShares Genomics Immunology and Healthcare ETF buyer in Q2 2025 was Portland Global Advisors, an estimated $2.06M added.
  • The largest iShares Genomics Immunology and Healthcare ETF seller in Q2 2025 was Morgan Stanley, an estimated $4.12M sold.

Based on aggregated 13F filings for Q2 2025.